ArticleDiscover oncology2025
Expression of interleukin 1-alpha, interleukin 6 and CD 10 in predicting recurrence of ameloblastoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeAmeloblastoma (AM) is a clinically significant odontogenic tumour known for its local invasive and high post-treatment recurrence risk. Despite advancements in surgical techniques, predicting recurrence remains challenging. The role of immunomarkers in predicting recurrence of ameloblastoma remains non-conclusive. The aim of this study is to investigate the predictability of recurrence using selected immune markers.
methods42 AM samples comprising 16 non-recurrent AM (AMNR), 13 primary tumour of recurrent AM (PAMR), and 13 recurrent AM from the same patient as PAMR (RAM) were immunohistochemically examined for the expression of interleukin 1-alpha (IL-1α), interleukin 6 (IL-6) and CD 10. Immunoreactive scoring (IRS) was used to assess the expression levels. The expression levels were further analyzed for the correlation with demographic and clinicopathological parameters of interest.
resultsThe three markers were heterogeneously expressed in the ameloblastoma samples (IL-1α = 97.6%; IL-6 = 97.6% and CD 10 = 90.5%). Major findings were the upregulation of IL-6 (RAM > PAMR > AMNR) in RAM, while IL-1α and CD 10 scored higher in AMNR (AMNR > PAMR > RAM). Further correlation with clinicopathological parameters showed significant association between IL-1α expression with histopathological variants in AMNR (p = 0.03) and PAMR (p = 0.002). IL-6 expression was significantly correlated with tumour locality in AMNR (p = 0.01), and CD 10 showed significant correlation with tumour locality in PAMR (p = 0.02) and subsites of tumour locality in PAMR (p = 0.005) and RAM (p = 0.002).
conclusionThe upregulation of IL-6 in recurrent ameloblastoma may predict its potential for recurrence. However, this interpretation should be considered tentative due to the inherent limitations of the study. Immunoexpression of IL-1α and CD 10 requires further investigation to elucidate their roles in tumourigenesis and invasiveness of ameloblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.